The Mosaic Company has deepened its push into biological crop solutions with a £2.5 million investment in UK-based start-up SugaROx, as part of its Series A round.
The investment will support SugaROx’s efforts to commercialise a first-in-class crop biostimulant based on a proprietary form of trehalose-6-phosphate (T6P) – a naturally occurring plant sugar that regulates carbon allocation and nutrient use within crops. For Mosaic, one of the world’s largest producers of phosphate and potash fertilisers, the deal strengthens an existing partnership and signals a clear intent to build out a complementary portfolio of biological technologies aimed at improving nutrient efficiency and crop performance.
Tackling one of biologicals’ biggest weaknesses
SugaROx stands out in a crowded and fast-growing biostimulants market by directly addressing a longstanding challenge: inconsistent field performance.
Many biological products struggle to deliver reliable results under real-world conditions, in part because their active ingredients cannot effectively penetrate plant cells. SugaROx’s approach combines a single, precisely manufactured active ingredient with a patented delivery system designed to enable rapid uptake into plant tissues.
“We are built around a single, precisely manufactured active ingredient,” co-founder and CTO Dr Cara Griffiths told AgTechNavigator. “What goes into the field is reproducibly the same each time,” she added, highlighting a key contrast with complex biological blends.
The company’s lead molecule works by inhibiting a famine-signalling enzyme, stimulating the movement of carbon and nutrients towards grain filling – a mechanism designed to improve both yield and quality.
From lab science to field performance
SugaROx’s technology originates from patented research developed at Oxford University and Rothamsted Research, giving it strong scientific foundations. But the company is equally focused on demonstrating consistent agronomic outcomes across diverse environments.
To date, trials have shown 3-15% yield improvements in wheat and barley, 3-8% in soybean and 2-4% in maize.
Across more than 40 trials, this translates into a roughly 70% success rate in delivering yield increases, reflecting a deliberate strategy to test across different soils, climates and farming systems.
Rather than eliminating variability, the company has designed its trial programme to capture it. “Biostimulants interact with plant metabolism… the response is shaped by genotype, environment and management,” Griffiths said.
The latest funding will allow SugaROx to scale this approach, expanding trials across five markets and generating the data needed for regulatory approval in the UK, EU and US ahead of a targeted UK launch in 2027-2028.
A natural fit for Mosaic’s evolving strategy
The investment aligns closely with Mosaic’s broader strategic shift beyond commoditised fertilisers.
In its first-quarter 2026 results, Mosaic highlighted growing ambitions for its Mosaic Biosciences platform, positioning it as a key pillar of long-term growth alongside its core nutrient business. The company said it expects to launch up to 10 new biological products this year, with revenues from the segment set to double.
Against this backdrop, SugaROx offers a compelling fit: a science-led, differentiated technology addressing nutrient use efficiency; a solution that can enhance the performance of fertiliser inputs; and a foothold in the emerging category of precision biostimulants.
Jeff Wheeler, vice president of Biosciences at Mosaic, described SugaROx as “advancing a new category… that aligns closely with our approach”, underscoring the strategic overlap.
From fertilisers to integrated crop solutions
For Mosaic, the deal reflects a broader industry transition: moving from selling nutrients to offering integrated solutions that optimise plant physiology and resource use.
This shift is being driven by multiple pressures, including volatile input costs, tightening farm margins and increasing demand for more sustainable cropping systems. Biologicals – particularly those that improve nutrient use efficiency – are seen as a critical tool in that transition.
Commercialisation still hinges on data
Despite strong early results, SugaROx still faces key hurdles before market entry, particularly around regulatory approval and large-scale validation.
In the UK, the absence of a formal regulatory framework for biostimulants places greater emphasis on field data and farmer confidence.
“That absence of a framework is in some ways an opportunity,” said Griffiths, “as there is no product approval hurdle equivalent to a pesticide registration. But it also means that market credibility will be built through the quality of our agronomic evidence rather than through a regulatory stamp of approval.”
The company has been working with independent partners including ADAS to generate multi-season, real-farm evidence.
The field validation programme is “central to our launch readiness,” Griffiths stressed, “and it is the most advanced aspect of our UK market preparation”.
The goal is to build a dataset that demonstrates consistent returns for growers, targeting a 3:1 return on investment, even at the lower end of yield improvement ranges. “Our confidence in farmer adoption at launch rests on a few things,” she explained: “The credibility of independent trial partners, a growing multi-season dataset that reflects real farm conditions, and a yield improvement range that, even at the conservative end, represents a meaningful return relative to product cost.
“We have a biostimulant that is more expensive than those currently on the market, however we believe our trial data packages will speak for themselves and will provide a 3:1 ROI for the grower, while continuing to work on our actives to make them as cost effective as possible, and deployable across all farm types in the UK and beyond.”
Backed to scale
Mosaic’s latest investment builds on an earlier £400,000 seed-round contribution in 2025, which helped SugaROx scale production from lab to pilot level.
With the Series A still open, the company is now focused on securing additional capital to complete development and bring its first products to market.
For Mosaic, the investment represents more than a financial stake – it is an early move in shaping a future where fertilisers are increasingly paired with biological solutions designed to make every unit of nutrient go further.
As the fertiliser sector navigates margin pressure and supply volatility, that combination could prove increasingly valuable.
